

Barcelona (Spain)  
30<sup>th</sup> March 2020

# Almirall to ensure business continuity of all drugs essential for patients

- **The Company will continue production of all its essential products, and has increased production of drugs such as paracetamol, which can help mitigate the symptoms of COVID-19**
- **A number of donations and collaborations in key markets have been launched to support healthcare professionals and mitigate the spread of the pandemic**

**Almirall, S.A. (ALM)** has announced today that despite the current situation generated by the spread of COVID-19, and in order to ensure the well-being of its patients, it will continue to produce all essential products. The Company has also increased production capabilities for specific medicines, such as paracetamol, which address symptoms of patients affected by COVID-19.

The Company has also triggered an action plan which includes a wide range of measures to respond to the COVID-19 pandemic and help mitigate its adverse effects, and to support the healthcare professionals fighting at the forefront of this crisis. These measures include:

- Donation of **Blastoactiva** and **Balneum** topical creams in Spain to help healthcare professionals reduce dry and damaged skin caused by masks, repeated handwashing and the use of sanitizers.
- **Donation of Balneum topical cream** in the United Kingdom.
- **Partial repurposing of production facilities in Germany, to manufacture antibacterial gels.**

Last week Almirall donated protective equipment for frontline healthcare workers, including masks, gloves and coats, among other items, to several institutions in Spain. In addition, the Company has announced further donations of medical supplies and personal protective equipment for frontline healthcare workers at *Sant Joan Despi Moisès Broggi Hospital* and *Martorell Hospital*, in order to assist and offer support to those professionals. Almirall's donation will provide **more than 11,000 health products for each hospital**, from technical gloves, white coats and Tyvek suits to rigid-frame safety glasses and *CRITICUM* medical provisions.

Almirall and the *Leitat Foundation* will also work together to develop 3D printed respirators for hospitals and intensive care units in the face of the current health emergency.

Almirall is working on leading and coordinating a global effort to support countries in the prevention, detection and response to the pandemic.

Almirall's focus is on all those people who have been directly and indirectly affected by this unprecedented health crisis. At Almirall, we are deploying all our talents and efforts to help our patients, healthcare professionals and partners during this crisis, and we will continue to do so until this difficult situation is over.

## About Almirall

Almirall is a leading skin-health focused global pharmaceutical company that partners with healthcare professionals, applying science to provide medical solutions to patients and future generations. Our efforts are focused on fighting skin health diseases and helping people feel better. We support healthcare professionals in their continuous improvements, providing our innovative solutions where they are needed.

The company was founded over 75 years ago and has its headquarters in Barcelona. It is listed on the Spanish Stock Exchange (ticker: ALM). Almirall has become a key source of value creation for society thanks to its commitment to its principal shareholders and its decision to help others by understanding their challenges and using science to provide solutions for real life. Total Revenues in 2019 were more than 900 million euros. Almirall has c. 1,800 employees.

For more information, please visit [almirall.com](https://www.almirall.com)

### Media contact:

LLYC  
Laia Romagosa  
[lromagosa@lorenteycuenca.com](mailto:lromagosa@lorenteycuenca.com)  
Phone: (+34) 91 563 77 22

### Corporate Communications contact:

Almirall  
Noel Ortiz  
[noel.ortiz@almirall.com](mailto:noel.ortiz@almirall.com)  
Phone: (+34) 93 291 30 00

### Investors' relations contact:

Almirall  
Pablo Divasson del Fraile  
[pablo.divasson@almirall.com](mailto:pablo.divasson@almirall.com)  
Phone: (+34) 93 291 30 87

### Legal warning

This document includes only summary information and is not intended to be exhaustive. The facts, figures and opinions contained in this document, in addition to the historical ones, are "forward-looking statements". These statements are based on the information currently available and the best estimates and assumptions that the Company considers reasonable. These statements involve risks and uncertainties beyond the control of the Company. Therefore, actual results may differ materially from those declared by such forward-looking statements. The Company expressly waives any obligation to revise or update any forward-looking statements, goals or estimates contained in this document to reflect any changes in the assumptions, events or circumstances on which such forward-looking statements are based, unless required by the applicable law.

If you wish to unsubscribe from any Almirall Corporate Communication click [here](#)

In accordance with the General Data Protection Regulation and the applicable local regulations, we inform you that your personal data is processed by Almirall S.A. with registered address at Ronda del General Mitre 151, -08022-, Barcelona (Spain), acting as Controller in line with the purposes indicated in our Privacy Policy. For further information, you may consult it at <https://www.almirall.com/privacy-policy> or contact our Data Protection Officer at the e-mail address: [dpo.global@almirall.com](mailto:dpo.global@almirall.com). PRNewswire is the Agency that licenses your personal data according to their privacy policy <https://gdpr.cision.com/gdpr>. At any time you can exercise your rights of access, rectification, deletion, objection, portability as well as the limitation of the processing of your data in the terms provided in the current regulations on Data Protection, by addressing the corresponding written request to our postal address (Ronda General Mitre, 151, 08022 Barcelona, Spain). The request to exercise any of your rights must be accompanied by a copy of an official document that identifies you (ID, driver's license or passport). Finally, we inform you that you can contact the Spanish Data Protection Agency and any other competent public bodies for any claim arising from the processing of your personal data.